Moldova - Rumania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

uzina de vitamine din kiev sap - lisinoprilum + amlodipinum - comprimate - 10 mg + 5 mg

Uni Eropa - Rumania - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agenți antitrombotici - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). supradenivelare de segment st infarct miocardic acut, în asociere cu aas în tratați medical, eligibili pentru tratamentul trombolitic. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pentru informații suplimentare vă rugăm să consultați secțiunea 5.

Uni Eropa - Rumania - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel clorhidrat - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenți antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Rumania - Rumania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

Rumania - Rumania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

Rumania - Rumania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - germania - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

Rumania - Rumania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - germania - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

Rumania - Rumania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

Rumania - Rumania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

Uni Eropa - Rumania - EMA (European Medicines Agency)

n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporoza, postmenopauză - medicamente pentru tratamentul bolilor osoase - tratamentul osteoporozei postmenopauzale la pacienții cu risc de insuficiență de vitamina d. adrovance reduce riscul fracturilor vertebrale și de șold.